Page last updated: 2024-11-13

gt0918

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

proxalutamide: has antineoplastic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60194102
CHEMBL ID4594417
SCHEMBL ID12494226
MeSH IDM000608301

Synonyms (27)

Synonym
SCHEMBL12494226
1398046-21-3
unii-qx6o64gp40
gt-0918
proxalutamide [who-dd]
qx6o64gp40 ,
proxalutamide
4-(4,4-dimethyl-3-(6-(3-(2-oxazolyl)propyl)-3-pyridinyl)-5-oxo-2-thioxo-1-imidazolidinyl)-3-fluoro-2-(trifluoromethyl)-benzonitrile
pruxelutamide [inn]
pruxelutamide
gt0918
kcbjgvdosbkvkp-uhfffaoysa-n
HY-103184
CS-0025229
4-[4,4-dimethyl-3-[6-[3-(1,3-oxazol-2-yl)propyl]pyridin-3-yl]-5-oxo-2-sulfanylideneimidazolidin-1-yl]-3-fluoro-2-(trifluoromethyl)benzonitrile
4-(4,4-dimethyl-3-(6-(3-(oxazol-2-yl)propyl)pyridin-3-yl)-5-oxo-2-thioxoimidazolidin-1-yl)-3-fluoro-2-(trifluoromethyl)benzonitrile
SB17303
4-(4,4-dimethyl-3-(6-(3-(oxazol-2-yl)propyl)pyridin-3-yl)-5-oxo-2-thioxoimidazolidin-1-yl)-3-fluoro-2-(trifluoromethyl) benzonitrile
Q27287540
AT29744
MS-29600
EX-A5434
CHEMBL4594417
gtpl11992
4-(4,4-dimethyl-3-{6-[3-(1,3-oxazol-2-yl)propyl]pyridin-3-yl}-5-oxo-2-sulfanylideneimidazolidin-1-yl)-3-fluoro-2-(trifluoromethyl)benzonitrile
DTXSID901102678
AKOS040741823

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" We extracted data on the trial and patient characteristics, and the following primary outcomes: all-cause mortality, the ratios of virological cure, and treatment-emergent adverse events."( Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials.
Chen, J; Cheng, Q; Fang, Z; Jia, Q; Zhao, G, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
"The aim of the present work was to design a pH-modified solid dispersion (pH(M)-SD) that can improve the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug."( Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: preparation, characterization and evaluation in vivo.
Fan, Y; Gao, C; Ge, Z; Gong, W; He, S; Huang, X; Shan, L; Tong, Y; Wang, Y; Yang, M, 2014
)
0.8
" The results showed that proxalutamide had good oral bioavailability and wide tissue distribution in vivo."( Quantitative determination of proxalutamide in rat plasma and tissues using liquid chromatography/tandem mass spectrometry.
Gu, S; Peng, Y; Sang, H; Sun, J; Wang, G; Wang, Y; Zhong, Y, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
", low dosage bamlanivimab, baricitinib, imatinib, and sotrovimab) are a better choice for treating severe or non-severe COVID-19 patients."( Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials.
Chen, J; Cheng, Q; Fang, Z; Jia, Q; Zhao, G, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (8.33)24.3611
2020's11 (91.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.01 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (33.33%)5.53%
Reviews2 (16.67%)6.00%
Case Studies2 (16.67%)4.05%
Observational0 (0.00%)0.25%
Other4 (33.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]